210 related articles for article (PubMed ID: 37147722)
1. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
Yoo J; Jeon J; Baik M; Kim J
Cardiovasc Diabetol; 2023 May; 22(1):106. PubMed ID: 37147722
[TBL] [Abstract][Full Text] [Related]
2. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
3. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study.
Ha J; Choi DW; Kim KY; Nam CM; Kim E
Cardiovasc Diabetol; 2021 Jul; 20(1):152. PubMed ID: 34315501
[TBL] [Abstract][Full Text] [Related]
5. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
Graham DJ; Ouellet-Hellstrom R; MaCurdy TE; Ali F; Sholley C; Worrall C; Kelman JA
JAMA; 2010 Jul; 304(4):411-8. PubMed ID: 20584880
[TBL] [Abstract][Full Text] [Related]
6. Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus.
Bae J; Park T; Kim H; Lee M; Cha BS
Diabetes Metab J; 2021 May; 45(3):326-336. PubMed ID: 33866775
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis.
Dutta D; Bhattacharya S; Kumar M; Datta PK; Mohindra R; Sharma M
Diabetes Metab Syndr; 2023 Jan; 17(1):102697. PubMed ID: 36580702
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis.
Lee M; Saver JL; Liao HW; Lin CH; Ovbiagele B
Stroke; 2017 Feb; 48(2):388-393. PubMed ID: 27999139
[TBL] [Abstract][Full Text] [Related]
9. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
10. Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.
Lee YH; Kim JH; Kim SR; Jin HY; Rhee EJ; Cho YM; Lee BW
J Korean Med Sci; 2017 Jan; 32(1):60-69. PubMed ID: 27914133
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
Hung YC; Chiu LT; Huang HY; Bau DT
Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
[TBL] [Abstract][Full Text] [Related]
16. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.
Dore DD; Trivedi AN; Mor V; Lapane KL
Pharmacotherapy; 2009 Jul; 29(7):775-83. PubMed ID: 19558251
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
[TBL] [Abstract][Full Text] [Related]
18. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
[TBL] [Abstract][Full Text] [Related]
19. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes.
Miao S; Dong X; Zhang X; Jing S; Zhang X; Xu T; Wang L; Du X; Xu H; Liu Y
J Diabetes; 2019 Aug; 11(8):684-689. PubMed ID: 30597747
[TBL] [Abstract][Full Text] [Related]
20. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension.
Jin SM; Park CY; Cho YM; Ku BJ; Ahn CW; Cha BS; Min KW; Sung YA; Baik SH; Lee KW; Yoon KH; Lee MK; Park SW
Diabetes Obes Metab; 2015 Jun; 17(6):599-602. PubMed ID: 25580775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
